Canakinumab to prevent clonal blood count problems turning into cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests canakinumab to help stop high-risk clonal cytopenias of unknown significance (CCUS) from progressing into a blood cancer. If you have persistent low blood counts and specific genetic features, this treatment may lower the chance of progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have high-risk CCUS
- You have unexplained low blood counts lasting more than 4 months (low red cells, low neutrophils, and/or low platelets)
- Your bone marrow findings do not fully meet criteria for MDS, and you have no history of blood cancer
- You have certain genetic mutations (from special testing) that increase the risk of progression
- You must be well enough to function (ECOG 0–2) and be able to consent
- Your organ function and blood tests meet key safety limits (kidney, liver, and bilirubin) and you do not have active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
This Phase 2 trial studies whether a statin medicine can help people with CCUS (a bone-marrow condition with abnormal genetic mutations) or lower-risk MDS (a blood disorder) that causes persistent low blood counts. It aims to see if statins can improve blood-related outcomes while keeping you safe from side effects.
This study follows adults who have certain blood-cell DNA changes (CHIP or CCUS) to learn how their condition may progress over time. It mainly looks at natural history—what happens in the blood without giving an active treatment.
This trial tests whether curcumin, a natural compound found in turmeric, can reduce inflammation and improve symptoms like fatigue in people with certain blood disorders that cause low blood counts or overproduction of blood cells. It is for patients with clonal cytopenia of uncertain significance, low-risk myelodysplastic syndrome, or myeloproliferative neoplasms (polycythemia vera, essential thrombocytosis, or myelofibrosis) who have bothersome symptoms.
This trial tests a drug called enasidenib for people who have had low blood counts for at least 6 months and have a specific mutation in the IDH2 gene. The study aims to see if the drug can improve blood counts and is done mostly from home with fewer clinic visits.
Hear when a new Clonal Cytopenia of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.